At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ZLAB Zai Lab Ltd
Market Closed 12-20 16:00:00 EST
26.72
+0.50
+1.91%
盘后25.65
-1.07-4.00%
17:42 EST
High27.33
Low25.96
Vol391.30K
Open26.43
D1 Closing26.22
Amplitude5.23%
Mkt Cap2.89B
Tradable Cap2.64B
Total Shares108.14M
T/O10.48M
T/O Rate0.40%
Tradable Shares98.74M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Zai Lab Announces Participation in Investor Conference in January 2025
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.